Guided Therapeutics (GTHP) 10-Q 15 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	8-May-14
Document And Entity Information	'	'
Entity Registrant Name	'GUIDED THERAPEUTICS INC	'
Entity Central Index Key	'0000924515	'
Document Type	'10-Q	'
Document Period End Date	31-Mar-14	'
Amendment Flag	'false	'
Current Fiscal Year End Date	'--12-31	'
Is Entity a Well-known Seasoned Issuer?	'No	'
Is Entity a Voluntary Filer?	'No	'
Is Entity's Reporting Status Current?	'Yes	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	72,172,331
Document Fiscal Period Focus	'Q1	'
Document Fiscal Year Focus	'2014	'

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
CURRENT ASSETS	'	'
Cash and cash equivalents	$50	$613
Accounts receivable, net of allowance for doubtful accounts of $18 at both March 31, 2014 and December 31, 2013	122	133
Inventory, net of reserves of $120 and $184, at March 31, 2014 and December 31, 2013, respectively	1,254	1,193
Other current assets	48	101
Total current assets	1,474	2,040
Property and equipment, net	807	920
Other assets	315	356
Total noncurrent assets	1,122	1,276
TOTAL ASSETS	2,596	3,316
CURRENT LIABILITIES:	'	'
Short-term notes payable	378	35
Current portion of long-term note payable	111	109
Accounts payable	1,268	891
Accrued liabilities	997	723
Deferred revenue	6	14
Total current liabilities	2,760	1,772
Warrants, at fair value	1,007	1,548
Long-term debt payable, less current portion	99	103
Total long-term liabilities	1,106	1,651
TOTAL LIABILITIES	3,866	3,423
STOCKHOLDERS' EQUITY :	'	'
Series B convertible preferred stock, $.001 par value; 3 shares authorized, 2 and 2 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively (liquidation preference of $1.7 million and $2.1 million at March 31, 2014 and December 31, 2013, respectively)	922	1,139
Common stock, $.001 Par value; 145,000 shares authorized, 71,770 and 70,479 shares issued and outstanding as of March, 31 2014 and December 31, 2013, respectively	72	71
Additional paid-in capital	102,503	101,840
Treasury stock, at cost	-132	-132
Accumulated deficit	-104,635	-103,025
TOTAL STOCKHOLDERS' EQUITY	-1,270	-107
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$2,596	$3,316

CONDENSED_CONSOLIDATED_BALANCE1

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified
CURRENT ASSETS	'	'
Accounts receivable, net of allowance	$18	$18
Inventory, net of reserves	$120	$184
STOCKHOLDERS' EQUITY :	'	'
Series B convertible preferred stock par value	$0.00	$0.00
Series B convertible preferred stock shares authorized	3	3
Series B convertible preferred stock, Issued	2	2
Series B convertible preferred stock, Outstanding	2	2
Common stock, par value	$0.00	$0.00
Common stock, Authorized	145,000	145,000
Common stock, Issued	71,770	70,479
Common stock, outstanding	71,770	70,479

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
REVENUE:	'	'
Contract and grant revenue	$19	$167
Sales - devices and disposables	122	132
Cost of goods sold	192	158
Gross Loss	-70	-26
OPERATING EXPENSES:	'	'
Research and development	607	813
Sales and marketing	283	164
General and administrative	1,138	1,039
Total	2,028	2,016
Operating loss	-2,079	-1,875
Other income	2	75
INTEREST EXPENSE	-27	-15
Change in fair value of warrants	542	'
Total other income	517	60
LOSS FROM OPERATIONS	-1,562	-1,815
PROVISION FOR INCOME TAXES	'	'
NET LOSS	-1,562	-1,815
PREFERRED STOCK DIVIDENDS	48	'
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	($1,610)	($1,815)
BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	($0.02)	($0.03)
WEIGHTED AVERAGE SHARES OUTSTANDING	71,451	63,671

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:	'	'
Net loss	($1,562)	($1,815)
Adjustments to reconcile net loss to net cash used in operating activities	'	'
Bad debt expense (recovery)	'	7
Depreciation and amortization	117	112
Stock based compensation	359	430
Change in fair value of warrants	-541	'
Changes in operating assets and liabilities:	'	'
Inventory	-61	85
Accounts receivable	11	-65
Other current assets	53	-49
Other assets	41	-30
Accounts payable	377	113
Deferred revenue	-8	25
Accrued liabilities	255	-126
Total adjustments	603	502
Net cash used in operating activities	-959	-1,313
CASH FLOWS FROM INVESTING ACTIVITIES:	'	'
Additions to fixed assets	-4	-101
Net cash used in investing activities	-4	-101
CASH FLOWS FROM FINANCING ACTIVITIES:	'	'
Proceeds from debt financing	378	'
Payments made on notes payable	-45	-169
Proceeds from options and warrants exercised	67	1,648
Net cash provided by financing activities	400	1,479
NET CHANGE IN CASH AND CASH EQUIVALENTS	-563	65
CASH AND CASH EQUIVALENTS, beginning of year	613	1,044
CASH AND CASH EQUIVALENTS, end of period	50	1,109
SUPPLEMENTAL SCHEDULE OF:	'	'
Cash paid for Interest	8	4
NONCASH INVESTING AND FINANCING ACTIVITIES:	'	'
Conversion of accrued expenses into common stock / options	22	'
Issuance of common stock as board compensation	'	$463

1_BASIS_OF_PRESENTATION

1. BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
1. BASIS OF PRESENTATION	'
	The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X by Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary InterScan, Inc., (“Interscan”) (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of March 31, 2014, results of operations for the three months ended March 31, 2014 and 2013, and cash flows for the three months ended March 31, 2014 and 2013. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results for a full fiscal year. Preparing financial statements requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. Actual results could differ from those estimates. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
	The Company's prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2014, it had an accumulated deficit of approximately $104.6 million. Through March 31, 2014, the Company has devoted substantial resources to research and development efforts. The Company does not have significant experience in manufacturing, marketing or selling its products. The Company's development efforts may not result in commercially viable products and it may not be successful in introducing its products. Moreover, required regulatory clearances or approvals may not be obtained. The Company's products may not ever gain market acceptance and the Company may not ever achieve levels of revenue to sustain further development costs and support ongoing operations or achieve profitability. The development and commercialization of the Company's products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue through the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals and conduct further research and development.
	Going Concern
	The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern.  The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Notwithstanding the foregoing, the Company believes it has made progress in recent years in stabilizing its financial situation by execution of multiyear contracts from Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo (“Konica Minolta”) and grants from the National Cancer Institute (“NCI”), while at the same time simplifying its capital structure and significantly reducing debt. However, the Company has replaced its prior agreements with Konica Minolta with a new licensing agreement, and therefore will no longer receive direct payments from Konica Minolta, and will have to pay a royalty to Konica Minolta should the Company sell any products licensed from Konica Minolta.
	At March 31, 2014, the Company had negative working capital of approximately $1.3 million and the stockholders’ deficit was approximately $1.3 million, primarily due to recurring net losses from operations, deemed dividends on warrants and preferred stock, offset by proceeds from the exercise of options and warrants. In addition, the Company is past due on payroll tax liabilities totaling $200,000.
	The Company’s capital-raising efforts are ongoing. If sufficient capital cannot be raised by the end of 2014, the Company has plans to curtail operations by reducing discretionary spending and staffing levels, and attempting to operate by only pursuing activities for which it has external financial support and additional NCI, NHI or other grant funding. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.
	The Company had warrants exercisable for approximately 11.6 million shares of its common stock outstanding at March 31,
	2014, with exercise prices of $0.40, $0.68, $0.80 and $1.08 per share. Exercises of these warrants would generate a total of approximately $7.9 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the private sale of preferred stock or debt securities, public and private sales of common stock, and grants, if available.
	Assuming the Company receives FDA approval for its LuViva cervical cancer detection device in 2014, the Company currently anticipates an early 2015 product launch in the United States. Product launch outside the United States began in the second half of 2013.

2_SIGNIFICANT_ACCOUNTING_POLIC

2. SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
2. SIGNIFICANT ACCOUNTING POLICIES	'
	The Company’s significant accounting policies were set forth in the audited financial statements and notes thereto for the year ended December 31, 2013 included in its annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”).
	Use of Estimates
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and Lattice Model calculations.
	Principles of Consolidation
	The accompanying consolidated financial statements, as of and for the quarter ended March 31, 2014, includes the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary.
	Accounting Standards Updates
	Newly effective accounting standards updates and those not effective until after March 31, 2014, are not expected to have a significant effect on the Company’s financial position or results of operations.
	Cash Equivalents
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
	Concentration of Credit Risk
	The Company, from time to time during the periods covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
	Inventory Valuation
	All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At March 31, 2014 and December 31, 2013 our inventories were as follows (in thousands):
			March 31,			December 31,
			2014			2013
	Raw materials	$	1,108		$	1,013
	Work in process		209			268
	Finished goods		57			96
	Inventory reserve		(120	)		(184	)
	Total	$	1,254		$	1,193
	Property and equipment
	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred.
	Revenues
	The majority of the Company’s revenues were from product sales of approximately $122,000, grants with NIH totaling approximately $13,000, as well as other income from royalties of approximately $5,000, for the three months ended March 31, 2014. Revenue for the same period in 2013, was from product sales of approximately $132,000, grants with NIH and NCI totaling approximately $97,000, as well as other income from royalty and miscellaneous receipts of approximately $70,000 for the three months ended March 31, 2013.
	Accounts Receivable
	The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts.
	Revenue Recognition
	Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. The Company recognizes revenue from contracts on a straight line basis, over the terms of the contract. The Company recognizes revenue from grants based on the grant agreement, at the time the expenses are incurred.
	Deferred Revenue
	The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.
	Income Taxes
	The Company accounts for income taxes in accordance with the liability method. Under the liability method, the Company recognizes deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. The Company establishes a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income. As of December 31, 2013, the Company had approximately $59.8 million of net operating loss (“NOL”) carry forward. There was no provision for income taxes at March 31, 2014. A full valuation allowance has been recorded related to any deferred tax assets created from the NOL.
	Stock Option Plan
	The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.
	Warrants
	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation model.

3_FAIR_VALUE_OF_FINANCIAL_INST

3. FAIR VALUE OF FINANCIAL INSTRUMENTS	3 Months Ended
	Mar. 31, 2014
Investments, All Other Investments [Abstract]	'
3. FAIR VALUE OF FINANCIAL INSTRUMENTS	'
	The guidance for fair value measurements, ASC820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value
	measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow:
		·	Level 1 – Quoted market prices in active markets for identical assets and liabilities;
		·	Level 2 – Inputs, other than level 1 inputs, either directly or indirectly observable; and
		·	Level 3 – Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use.
	The Company records its derivative activities at fair value, which consisted of warrants as of March 31, 2014. The fair value of the warrants was estimated using the Monte Carlo Simulation model. Gains and losses from derivative contracts are included in net gain (loss) from derivative contracts in the statement of operations. The fair value of the Company’s derivative warrants is classified as a Level 3 measurement, since unobservable inputs are used in the valuation.
	The following table presents the fair value for those liabilities measured on a recurring basis as of March 31, 2014 and December 31, 2013:
	FAIR VALUE MEASUREMENTS ( In Thousands)
	Description			Level 1		Level 2		Level 3			Total			Asset/(Liability)
														Total
		Warrants		$	—	$	—	$	(1,548	)	$	(1,548	)	$	(1,548	)	31-Dec-13
		Warrants		$	—	$	—	$	(1,007	)	$	(1,007	)	$	(1,007	)	31-Mar-14

4_STOCK_OPTIONS

4. STOCK OPTIONS	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
4. STOCK OPTIONS	'
	The Company records compensation expense related to options granted to non-employees based on the fair value of the award.
	Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently, based on fair value estimates.
	For the quarter ended March 31, 2014 and 2013, stock-based compensation for options attributable to employees, officers and directors was approximately $298,000 and $430,000, respectively.  Compensation costs for stock options, which vest over time, are recognized over the vesting period. As of March 31, 2014, the Company had approximately $1.5 million of unrecognized compensation cost related to granted stock options, to be recognized over the remaining vesting period of approximately three years.
	The Company has a 1995 stock option plan (the “Plan”) approved by its stockholders for officers, directors and key employees of the Company and consultants to the Company.  Participants are eligible to receive incentive and/or nonqualified stock options.  The aggregate number of shares that may be granted under the Plan is 13,255,219 shares.  The Plan is administered by the compensation committee of the board of directors.  The selection of participants, grant of options, determination of price and other conditions relating to the exercise of options are determined by the compensation committee of the board of directors and administered in accordance with the Plan.
	Both incentive stock options and non-qualified options granted to employees, officers and directors under the Plan are exercisable for a period of up to 10 years from the date of grant, at an exercise price that is not less than the fair market value of the common stock on the date of the grant.  The options typically vest in installments of 1/48 of the options outstanding every month. Certain option granted to management vest based upon market and performance conditions.
	A summary of the Company’s activity under the Plan as of March 31, 2014 and changes during the three months then ended is as follows:
				Weighted
			Weighted	average	Aggregate
			average	remaining	intrinsic
			exercise	contractual	value
		Shares	price	(years)	(thousands)
	Outstanding, January 1, 2014	6,531,192	$          0.66	6.97	$     625,412
	Granted	2,109,511	0.51
	Exercised / Expired	-220,000	0.3
	Outstanding, March 31, 2014	8,420,703	$          0.63	6.97	$     558,747
	Vested and exercisable, March 31, 2014	5,771,724	$          0.61	5.85	$     558,747
	The Company estimates the fair value of stock options using a Black-Scholes and Lattice valuation models. Key input assumptions used to estimate the fair value of stock options include the expected term, expected volatility of the Company’s stock, the risk free interest rate, option forfeiture rates, and dividends, if any. The expected term of the options is based upon the historical term until exercise or expiration of all granted options. The expected volatility is derived from the historical volatility of the Company’s stock on the OTCBB market for a period that matches the expected term of the option. The risk-free interest rate is the constant maturity rate published by the U.S. Federal Reserve Board that corresponds to the expected term of the option.

5_LITIGATION_AND_CLAIMS

5. LITIGATION AND CLAIMS	3 Months Ended
	Mar. 31, 2014
Notes to Financial Statements	'
5. LITIGATION AND CLAIMS	'
	From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular period.
	As of March 31, 2014 and December 31, 2013, there was no accrual recorded for any potential losses related to pending litigation.

6_STOCKHOLDERS_EQUITY

6. STOCKHOLDERS' EQUITY	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
6. STOCKHOLDERS' EQUITY	'
	Common Stock
	The Company has authorized 145 million shares of common stock with $0.001 par value, 71,770,239 of which were outstanding as of March 31, 2014. During the three months ended March 31, 2014, the Company issued 220,000 shares in connection with the exercise of outstanding options.
	For the three months ended March 31, 2014, the Company issued 1,025,002 shares of common stock for its Series B preferred stock conversion, as well as 46,276 shares of common stock as payment of accrued dividends on the Series B preferred stock.
	Preferred Stock; Series B Convertible Preferred Stock
	The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of preferred stock as redeemable convertible preferred stock, none of which remain outstanding, and 3,000 shares of preferred stock as Series B Preferred Stock, of which 1,737 and 2,147 shares were issued and outstanding as of March 31, 2014 and December 31, 2013 respectively.
	Pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations, Preferences and Rights designating the Preferred Stock (the “Preferred Stock Designation”), shares of Series B Preferred Stock are convertible into common stock by their holder at any time, and will be mandatorily convertible upon the achievement of certain conditions, including the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock. The original conversion price was $0.68 per share, such that each share of Preferred Stock would convert into 1,471 shares of common stock, subject to customary adjustments, including any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Preferred Stock Designation. As a result of anti-dilution provisions, the current conversion price is set at $0.40 per share, such that each share of Preferred Stock would convert into 2,500 shares of common stock.
	Holders of the Series B Preferred Stock are entitled to quarterly dividends at an annual rate of 10.0%, payable in cash or, subject to certain conditions, common stock, at the Company’s option. Accrued dividends totaled approximately $53,000 at March 31, 2014. Each share of Series B Preferred Stock is entitled to a number of votes equal to the number of shares of common stock into which the Series B Preferred Stock is convertible. As long as shares of the Series B Preferred Stock are outstanding, and until the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock, the Company may not incur indebtedness for borrowed money secured by the Company’s intellectual property or in excess of $2.0 million without the prior consent of the holders of two-thirds of the outstanding shares of Series B Preferred Stock. The Company may redeem the Series B Preferred Stock after the second anniversary of issuance, subject to certain conditions. Upon the Company’s liquidation or sale to or merger with another corporation, each share of Series B Preferred Stock will be entitled to a liquidation preference of $1,000 per share, plus any accrued but unpaid dividends.
	The Series B Preferred Stock was issued with Tranche A warrants to purchase 1,858,089 shares of common stock and Tranche B warrants purchasing 1,858,088 shares of common stock, both at an exercise price of $1.08 per share. Pursuant to the terms of the Tranche B warrants, their exercise price will be reduced, and the number of shares of common stock into which those warrants are exercisable will be increased, if the Company issues shares at a price below the then-current exercise price. The exercise price of Tranche B warrants is currently $0.40 per share, convertible into 5,016,840 shares of common stock. As a result of these provisions, the Company is required to account for the warrants as a liability recorded at fair value each period. The Company values the warrants using a Monte Carlo Simulation model. Of the $2.6 million in proceeds from issuance of the Series B Preferred Stock, the Company originally allocated $873,000 to the fair value of the warrants. At March 31, 2014 and December 31, 2013, the fair value of these warrants was approximately $1.0 million and $1.5 million, respectively.
	Stock Options
	See Note 4, Stock Options.
	Warrants
	We have issued warrants to purchase our common stock from time to time in connection with certain financing arrangements.
	The Company had the following shares reserved for the warrants as of March 31, 2014:
	Warrants		Exercise Price	Expiration Date
	(Underlying Shares)
	471,856	-1	$0.80 per share	26-Jul-14
	3,590,522	-1	$0.80 per share	1-Mar-15
	6,790	-2	$1.01 per share	10-Sep-15
	439,883	-3	$0.68 per share	31-Mar-16
	285,186	-4	$1.05 per share	20-Nov-16
	1,858,089	-5	$1.08 per share	23-May-18
	5,016,840	-6	$0.40 per share	23-May-18
	__________
	(1)     Consists of outstanding warrants issued in connection with a warrant exchange program in June 2012.
		-2	Consists of outstanding warrants issued in conjunction with a private placement on September 10, 2010.
		-3	Consists of outstanding warrants issued in conjunction with a buy back of our minority interest in our subsidiary in December 2012, which were issued in February 2014.
		-4	Consists of outstanding warrants issued in conjunction with a private placement on November 21, 2011.
		-5	Consists of outstanding warrants issued in conjunction with a private placement on May 24, 2013.
		-6	Consists of outstanding warrants issued in conjunction with a private placement on May 24, 2013. Underlying shares increased from 1,858,089 to 5,016,840, and exercise price decreased from $1.08 per share to $0.40 per share, pursuant to the terms of the warrants, as a result of a 2013 warrant exchange program.

7_LOSS_PER_COMMON_SHARE

7. LOSS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2014
Earnings Per Share [Abstract]	'
7. LOSS PER COMMON SHARE	'
	Basic net loss per share attributable to common stockholders amounts are computed by dividing the net loss plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of common shares outstanding during the period.

8_NOTES_PAYABLE

8. NOTES PAYABLE	3 Months Ended
	Mar. 31, 2014
Debt Disclosure [Abstract]	'
8. NOTES PAYABLE	'
	Short Term Notes Payable
	At March 31, 2014, the Company maintained notes payable and accrued interest to related parties totaling $177,000 and third parties totaling $ 201,000. These notes are short term, straight-line amortizing notes. The notes carry an annual interest rate of 10%.
	Notes Payable
	At December 31, 2012, the Company was past due on two short-term notes totaling approximately $419,000 of principal and accrued interest. Interest charged on these notes prior to amendment ranged between 15-18%. On February 27, 2013, the Company renegotiated one of the two past due notes. The new note accrued interest at 6% and was paid in full during the quarter ended June 30, 2013. On April 16, 2013, the Company renegotiated the other note. The renegotiated note accrues interest at 9.0%, with a 16.0% default rate, requires monthly payments of $10,000, including interest, and matures November 2015. The balance due on this note was approximately $203,000 and $208,000 at March 31, 2014 and December 31, 2013, respectively. As of March 31, 2014, the note is accruing interest at the default rate, of which $63,000 is payable during the year ending December 31, 2014 and $105,000 is payable during the year ending December 31, 2015.

9_SUBSEQUENT_EVENTS

9. SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2014
Subsequent Events [Abstract]	'
9. SUBSEQUENT EVENTS	'
	On April 23, 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”), with Hanover Holdings I, LLC, an affiliate of Magna Group (“Magna”). Pursuant to the Purchase Agreement, the Company sold Magna a senior convertible note with an initial principal amount of $1.5 million (the “Initial Convertible Note”), for a purchase price of $1.0 million (an approximately 33.3% original issue discount). Additionally, Magna is irrevocably bound to purchase, on the tenth trading day after the effective date of a resale registration statement, an additional senior convertible note with an initial principal amount of $2.0 million and an 18-month term (the “Additional Convertible Note” and, with the Initial Convertible Note, the “Convertible Notes”), for a fixed purchase price of $2.0 million, subject only to conditions outside of Magna’s control or that Magna cannot cause not to be satisfied, none of which are related to the market price of the Company’s common stock.
	With respect to the Initial Convertible Note, $200,000 of the outstanding principal amount (together with any accrued and unpaid interest with respect to such portion of the principal amount) was automatically extinguished (without any cash payment by the Company) once the Company properly filed a registration statement with the SEC on April 30, 2014 covering the resale by Magna of shares of the Company’s common stock issued or issuable upon conversion of the Convertible Notes and (2) no event of default, or an event that with the passage of time or giving of notice would constitute an event of default, had occurred on or prior to such date. Moreover, $300,000 of the outstanding principal amount of the Initial Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) was automatically extinguished (without any cash payment by the Company) once the resale registration statement was declared effective by the SEC on May 12, 2014 and the prospectus contained therein became available for use by Magna for its resale of the shares of common stock issued or issuable upon conversion of the Convertible Notes and (2) no event of default, or an event that with the passage of time or giving of notice would constitute an event of default, had occurred on or prior to such date.
	The Initial Convertible Note matures on October 23, 2015 (subject to extension as provided in the Initial Convertible Note) and, in addition to the approximately 33.3% original issue discount, accrues interest at an annual rate of 6.0%. If issued, the Additional Convertible Note will mature 18 months from the date of issuance and will accrue interest at the same rate. The Convertible Notes are convertible at any time, in whole or in part, at Magna’s option, into shares of the Company’s common stock, at a conversion price equal to the lesser of $0.55 per share and a discount from the lowest daily volume-weighted average price of the Company’s common stock in the five trading days prior to conversion. The discount is 20% if the conversion takes place prior to December 19, 2014, and 25% if after that date. At no time will Magna be entitled to convert any portion of the Convertible Notes to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than 9.99% of the outstanding shares of the Company’s common stock as of such date. As long as Magna or its affiliates beneficially own any of the shares issued upon conversion, they may not engage in any “short sale” transactions in the Company’s common stock and may not sell more than the greater of $15,000 or 15% of the trading volume of the common stock in any single trading day.
	The Initial Convertible Note includes and, if issued, the Additional Convertible Note will include, customary event of default provisions. The Initial Convertible Note provides and, if issued, the Additional Convertible Note will provide for a default interest rate of 16%. Upon the occurrence of an event of default, Magna may require the Company to pay in cash the “Event of Default Redemption Price” which is defined in the Convertible Notes to mean the greater of (i) the product of (A) the amount to be redeemed multiplied by (B) 135% (or 100% if an insolvency related event of default) and (ii) the product of (X) the conversion price in effect at that time multiplied by (Y) the product of (1) 135% (or 100% if an insolvency related event of default) multiplied by (2) the greatest closing sale price of the common stock on any trading day during the period commencing on the date immediately preceding such event of default and ending on the date the Company makes the entire payment required to be made under this provision.
	The Company has the right at any time to redeem all or a portion of the total outstanding amount then remaining under the Convertible Notes in cash at a 25% premium.
	The Company paid to Magna a commitment fee for entering into the Purchase Agreement equal to 5% of the total purchase price for the Convertible Notes under the Purchase Agreement in the form of 321,820 shares of common stock (the “Commitment Shares”), calculated using a per share price of $0.465, representing the average of the daily volume-weighted average prices of a share of common stock for the second trading day immediately preceding closing date for the transaction. The Company also paid $50,000 of reasonable attorneys’ fees and expenses incurred by Magna in connection with the transaction.
	The Purchase Agreement contains customary representations, warranties and covenants by, among and for the benefit of the parties. The Purchase Agreement also provides for indemnification of Magna and its affiliates in the event that Magna incurs losses, liabilities, obligations, claims, contingencies, damages, costs and expenses related to the Company’s breach of any of its representations, warranties or covenants under the Purchase Agreement.

2_SIGNIFICANT_ACCOUNTING_POLIC1

2. SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Use of Estimates	'
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and Lattice Model calculations.
Principles of Consolidation	'
	The accompanying consolidated financial statements, as of and for the quarter ended March 31, 2014, includes the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary.
Accounting Standards Updates	'
	Newly effective accounting standards updates and those not effective until after March 31, 2014, are not expected to have a significant effect on the Company’s financial position or results of operations.
Cash Equivalents	'
	The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Concentration of Credit Risk	'
	The Company, from time to time during the periods covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation	'
	All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis.  Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At March 31, 2014 and December 31, 2013 our inventories were as follows (in thousands):
			March 31,			December 31,
			2014			2013
	Raw materials	$	1,108		$	1,013
	Work in process		209			268
	Finished goods		57			96
	Inventory reserve		(120	)		(184	)
	Total	$	1,254		$	1,193
Property and equipment	'
	Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred.
Revenues	'
	The majority of the Company’s revenues were from product sales of approximately $122,000, grants with NIH totaling approximately $13,000, as well as other income from royalties of approximately $5,000, for the three months ended March 31, 2014. Revenue for the same period in 2013, was from product sales of approximately $132,000, grants with NIH and NCI totaling approximately $97,000, as well as other income from royalty and miscellaneous receipts of approximately $70,000 for the three months ended March 31, 2013.
Accounts Receivable	'
	The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts.
Revenue Recognition	'
	Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. The Company recognizes revenue from contracts on a straight line basis, over the terms of the contract. The Company recognizes revenue from grants based on the grant agreement, at the time the expenses are incurred.
Deferred Revenue	'
	The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.
Income Taxes	'
	The Company accounts for income taxes in accordance with the liability method. Under the liability method, the Company recognizes deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. The Company establishes a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income. As of December 31, 2013, the Company had approximately $59.8 million of net operating loss (“NOL”) carry forward. There was no provision for income taxes at March 31, 2014. A full valuation allowance has been recorded related to any deferred tax assets created from the NOL.
Stock Option Plan	'
	The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.
Warrants	'
	The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation model.

2_SIGNIFICANT_ACCOUNTING_POLIC2

2. SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Inventory Valuation	'
			March 31,			December 31,
			2014			2013
	Raw materials	$	1,108		$	1,013
	Work in process		209			268
	Finished goods		57			96
	Inventory reserve		(120	)		(184	)
	Total	$	1,254		$	1,193

3_FAIR_VALUE_OF_FINANCIAL_INST1

3. FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	3 Months Ended
	Mar. 31, 2014
Investments, All Other Investments [Abstract]	'
Schedule fo fair value for liabilities measured on a recurring basis	'
	Description		Level 1		Level 2		Level 3			Total			Asset/(Liability)
													Total
		Warrants	$	—	$	—	$	(1,548	)	$	(1,548	)	$	(1,548	)	31-Dec-13
		Warrants	$	—	$	—	$	(1,007	)	$	(1,007	)	$	(1,007	)	31-Mar-14

4_STOCK_OPTIONS_Tables

4. STOCK OPTIONS (Tables)	3 Months Ended
	Mar. 31, 2014
Stock Options Tables	'
Stock Options activity	'
				Weighted
			Weighted	average	Aggregate
			average	remaining	intrinsic
			exercise	contractual	value
		Shares	price	(years)	(thousands)
	Outstanding, January 1, 2014	6,531,192	$          0.66	6.97	$     625,412
	Granted	2,109,511	0.51
	Exercised / Expired	-220,000	0.3
	Outstanding, March 31, 2014	8,420,703	$          0.63	6.97	$     558,747
	Vested and exercisable, March 31, 2014	5,771,724	$          0.61	5.85	$     558,747

6_STOCKHOLDERS_EQUITY_Tables

6. STOCKHOLDERS' EQUITY (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Outstanding warrants	'
	Warrants		Exercise Price	Expiration Date
	(Underlying Shares)
	471,856	-1	$0.80 per share	26-Jul-14
	3,590,522	-1	$0.80 per share	1-Mar-15
	6,790	-2	$1.01 per share	10-Sep-15
	439,883	-3	$0.68 per share	31-Mar-16
	285,186	-4	$1.05 per share	20-Nov-16
	1,858,089	-5	$1.08 per share	23-May-18
	5,016,840	-6	$0.40 per share	23-May-18

2_SIGNIFICANT_ACCOUNTING_POLIC3

2. SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Accounting Policies [Abstract]	'	'
Raw materials	$1,108	$1,013
Work in process	209	268
Finished goods	57	96
Inventory reserve	-120	-184
Total	$1,254	$1,193

3_FAIR_VALUE_OF_FINANCIAL_INST2

3. FAIR VALUE OF FINANCIAL INSTRUMENTS (Details)	Mar. 31, 2014	Dec. 31, 2013
Warrants	-1,007	-1,548
Level 1	'	'
Warrants	'	'
Level 2	'	'
Warrants	'	'
Level 3	'	'
Warrants	-1,007	-1,548

4_STOCK_OPTIONS_Details_Narrat

4. STOCK OPTIONS (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Notes to Financial Statements	'	'
Stock based compensation	$298,000	$430,000
Unrecognized compensation cost	$1,500,000	'

4_STOCK_OPTIONS_Details

4. STOCK OPTIONS (Details) (USD $)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Outstanding beginning balance, Shares	6,531,192
Granted, Shares	2,109,511
Exercised, Shares	-220,000
Outstanding ending balance, Shares	8,420,703
Vested and exercisable ending balance	5,771,724
Outstanding beginning balance, Weighted average exercise price	$0.66
Granted, Weighted average exercise price	$0.51
Exercised, Weighted average exercise price	$0.30
Outstanding ending balance, Weighted average exercise price	$0.63
Vested and exercisable ending balance	$0.61
Weighted Average Remaining Contractual Life (in years) Outstanding	'6 years 11 months 19 days
Weighted Average Remaining Contractual Life (in years) Exercisable	'5 years 10 months 6 days
Aggregate Intrinsic Value Outstanding, Beginning	$625,412
Aggregate Intrinsic Value Outstanding, Ending	558,747
Aggregate Intrinsic Value Exercisable	$558,747

6_STOCKHOLDERS_EQUITY_Details

6. STOCKHOLDERS' EQUITY (Details ) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 30, 2014	Mar. 31, 2014	Mar. 31, 2014	Mar. 31, 2014
			Warrant1Member	Warrant 2 [Member]	Warrant 3 [Member]	Warrant 4 [Member]	Warrant 5 [Member]	Warrant 6 [Member]	Warrant 7 [Member]
Warrants outstanding	8,420,703	6,531,192	471,856	3,590,522	6,790	439,883	285,186	1,858,089	5,016,840
Warrants exercise price	$0.63	$0.66	$0.80	$0.80	$1.01	$0.68	$1.05	$1.08	$0.40
Expiration date	'	'	26-Jul-14	1-Mar-15	10-Sep-15	31-Mar-16	20-Nov-16	23-May-18	23-May-18

8_NOTES_PAYABLE_Details_Narrat

8. NOTES PAYABLE (Details Narrative) (USD $)	Mar. 31, 2014
Debt Disclosure [Abstract]	'
Loan outstanding	$177,000
Notes payble	$201,000
Interest rate	10.00%